TA和NP方案治疗晚期复发转移性乳腺癌近期疗效观察

Comparative short-term therapeutic efficacy of TA and NP regimens for treatment of recurrent metastatic breast cancer in its late stage

关键词:  乳腺肿瘤  药物疗法  复发  肿瘤转移

Key words:  breast neoplasms/DT  recurrence  neoplasm metastasis

摘要:

［目的］观察比较TA和NP两组方案治疗复发转移性乳腺癌的疗效和毒性。［方法］127例晚期复发转移性乳腺癌随机分为TA（紫衫醇+表阿霉素）和NP（NVB+DDP）两组。［结果］TA组有效率为62.5％，NP组为58.73％，两组差异无显著性（P>0.01）。中位缓解期TA组为10.5（6～12.5）个月、NP组为9（4.5～11.5）个月，两组差异无显著性。不良反应主要为骨髓抑制和消化道反应，Ⅲ—Ⅳ度白细胞下降TA组为56.25％、NP组为49.2％，两组间差异无显著性（P>0.05）；Ⅲ—Ⅳ血小板下降率TA组为7.81％、NP组4.76％，两组间差异无显著性（P>0.05）。Ⅲ—Ⅳ度消化道反应两组发生率分别为18.75％和14.29％，且以Ⅲ度为主，未见心脏及肝脏损害。［结论］TA和NP两组方案治疗复发转移性乳腺癌疗效高且相似，但两组无统计学意义。两组方案均可作为治疗复发转移性乳腺癌的较佳方案。

Abstract:

［Objective］To observe and compare the therapeutic efficacy and toxicity of TA(TAT+EPZ) and NP(NVB+DDP) regimens in the treatment of recurrent metastatic breast cancer(R MBS).［Methods］We randomly divide 127 cases of RMBC in late stage into two groups: TA and NP.［Results］The effective rate of therapy in TA group was 62.5%(40/64) and that in NP group was 58.73%(37/63), respectively. NO statistically significant difference was found between both (P>0.01). Median duration of remission in TA group was 10.5 months and that in NP group was 9 months, showing no significant discrepancy between both. The adverse reactions were mainly myelogenic suppression and disorders of digestive tract, 56.25% of TA and 49.2% of NP group displayed grade Ⅲ、Ⅳ leukopenia (P>0.05). Grade Ⅲ～Ⅳ thrombocy topenia occurred in 7.81% of TA group and 4.76% of NP group (P>0.05). The occurrence rate of grade Ⅲ～Ⅳ digestive response was 18.75% in TA group and 14.29% in NP group (P>0.05), however,grade Ⅲ was predominately observed. ［Conclusion］Better but similar therapeutic efficacy has been obtained in patients with RMBC treated by TA and NP regimens.Although the median duration of survival in TA group seems rather longer than in NP group,there is no statistical significance yet.Both regimens can be used as more effective and tolerable ones in the treatment of RMBC.